Filtered By:
Cancer: Adenocarcinoma
Drug: Alimta
This page shows you your search results in order of date.
Order by Relevance | Date
Total 55 results found since Jan 2013.
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Conclusion: Chemotherapy agents have different effects on the expression of ICP ligands in tumor cells with different pathological types, and this may affect the efficacy of combined immunotherapy. These results provide a theoretical basis for further selection and optimization of the combination of chemotherapy and immunotherapy.PMID:37728201 | DOI:10.1177/15330338231202307
Source: Technology in Cancer Research and Treatment - September 20, 2023 Category: Cancer & Oncology Authors: Yu Zhao Zhe Wang Xiuhuan Shi Ting Liu Wenwen Yu Xiubao Ren Hua Zhao Source Type: research
Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC
This study suggests that NSCLC patients with both high TS expression and EGFR-driving mutations might benefit more from a combination strategy of EGFR-TKI and pemetrexed-based chemotherapy than EGFR-TKI monotherapy, which has profound clinical implications and therapeutic value.PMID:37278440 | DOI:10.1111/jcmm.17799
Source: Molecular Medicine - June 6, 2023 Category: Molecular Biology Authors: Yun Chen Chen Zhang Shidai Jin Jun Li Jiali Dai Zhihong Zhang Renhua Guo Source Type: research
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With < em > EGFR < /em > Mutations
CONCLUSION: Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.PMID:37235976 | DOI:10.1200/JCO.22.02547
Source: Clinical Lung Cancer - May 26, 2023 Category: Cancer & Oncology Authors: Lecia V Sequist James Chih-Hsin Yang Nobuyuki Yamamoto Kenneth O'Byrne Vera Hirsh Tony Mok Sarayut Lucien Geater Sergey Orlov Chun-Ming Tsai Michael Boyer Wu-Chou Su Jaafar Bennouna Terufumi Kato Vera Gorbunova Ki Hyeong Lee Riyaz Shah Dan Massey Victoria Source Type: research
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122)
CONCLUSION: ANTELOPE will provide efficacy outcomes of the current standard-of-care for the specific subset of TTF-1 negative NSCLC/ADC in a head-to-head comparison of approved immunochemotherapy regimens.PMID:37169628 | DOI:10.1016/j.cllc.2023.04.009
Source: Clinical Lung Cancer - May 11, 2023 Category: Cancer & Oncology Authors: Nikolaj Frost Annalen Bleckmann Frank Griesinger Christian Groh é Melanie Janning Jens Kollmeier Niels Reinmuth Martin Sebastian Michael Thomas Martin Reck Source Type: research
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer
CONCLUSION: In advanced NSCLC, cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cisplatin/gemcitabine. This is the first prospective phase III study in NSCLC to show survival differences based on histologic type.PMID:37146426 | DOI:10.1200/JCO.22.02544
Source: Clinical Lung Cancer - May 5, 2023 Category: Cancer & Oncology Authors: Giorgio Vittorio Scagliotti Purvish Parikh Joachim von Pawel Bonne Biesma Johan Vansteenkiste Christian Manegold Piotr Serwatowski Ulrich Gatzemeier Raghunadharao Digumarti Mauro Zukin Jin S Lee Anders Mellemgaard Keunchil Park Shehkar Patil Janusz Rolski Source Type: research
Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy
Int J Cancer. 2023 Apr 20. doi: 10.1002/ijc.34536. Online ahead of print.ABSTRACTTreatments for NSCLC patients with EGFR-TKI resistance are limited. Given that immunotherapy and antiangiogenic agents may have synergistic antitumor effects, we aimed to analyze the effect of multi-target angiogenesis inhibitor anlotinib and immune checkpoint inhibitors (ICIs) combination therapy in NSCLC patients who failed EGFR-TKI. The medical records of lung adenocarcinoma (LUAD) patients with EGFR-TKI resistance were reviewed. After EGFR-TKI resistance, patients who simultaneously received anlotinib and ICIs were enrolled in the observat...
Source: Cancer Control - April 20, 2023 Category: Cancer & Oncology Authors: Lian Yu Yaohua Hu Jianlin Xu Rong Qiao Hua Zhong Baohui Han Jinjing Xia Runbo Zhong Source Type: research
A combination of anti-PD-1 therapy and apatinib successfully treated a patient with EGFR mutation-negative advanced lung adenocarcinoma: A case report
J Cancer Res Ther. 2023 Feb;19(1):141-143. doi: 10.4103/jcrt.jcrt_1710_21.ABSTRACTHere, we report the case of a patient with advanced lung adenocarcinoma with negative driver genes, who benefited from treatment with anti-programmed cell death-1 (anti-PD-1) therapy combined with a low dose of apatinib. From February 2020, the patient was treated with camrelizumab combined with pemetrexed disodium. The treatment regimen was adjusted to camrelizumab combined with a low dose of apatinib every 3 weeks because the patient could not tolerate the side effects of the previous chemotherapy, and camrelizumab led to reactive cutaneous...
Source: Cell Research - April 3, 2023 Category: Cytology Authors: Jian Wang Shancheng Li Lei Zhang Xikun Zhang Source Type: research
Predictive factors associated with pemetrexed acute toxicity
CONCLUSION: To conclude, ELT induced by pemetrexed-based treatments occur frequently in cancer patients in a real-world setting. A pretherapeutic assessment before pemetrexed initiation should include three major checkpoints: use of proton pump inhibitors, sarcopenia, and denutrition evaluation.PMID:36951965 | DOI:10.1007/s00228-023-03478-4
Source: Clinical Lung Cancer - March 23, 2023 Category: Cancer & Oncology Authors: Mathilde Bonnet Anne Jouinot Pascaline Boudou-Rouquette Vanessa Seif Cl émentine Villeminey Jennifer Arrondeau Michel Vidal Rui Batista Marie Wislez Benoit Blanchet Fran çois Goldwasser Audrey Thomas-Schoemann Source Type: research
Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study
CONCLUSIONS: Neoadjuvant pembrolizumab plus chemotherapy could be considered reliable for clinical stage III NSCLC, but needs to be validated with more robust clinical trials.PMID:36762056 | PMC:PMC9903088 | DOI:10.21037/tlcr-22-871
Source: Cell Research - February 10, 2023 Category: Cytology Authors: Guangyin Zhao Hongyu Zhang Fengkai Xu Chunlai Lu Qiaoliang Zhu Francesco Grossi Duilio Divisi Teng Ma Jie Gu Di Ge Source Type: research
Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study
CONCLUSIONS: Intrathecal pemetrexed at a dose of 30 mg via Ommaya reservoirs on Days 1 and 8 every 21 days achieved promising disease control and satisfactory survival with moderate toxicities in resistant LUAD-LM, providing a feasible and effective option, especially for the patients who cannot tolerate LP.PMID:36588048 | DOI:10.1016/j.cllc.2022.11.011
Source: Cancer Control - January 1, 2023 Category: Cancer & Oncology Authors: Huiying Li Shengnan Zheng Yongjuan Lin Tingting Yu Yu Xie Cheng Jiang Xiangyu Liu Xiaoping Qian Zhenyu Yin Source Type: research
